BioCardia’s R&D Spend Up 13% as CardiAM Trials Show p-Value 0.02, 0.01
CardiAM therapy data from three trials in ischemic heart failure showed significant function improvements (p=0.02, 0.01), prompting launch of the CardiA HF2 study and regulatory discussions. Total expenses rose 3% to $8.3M and R&D spending climbed 13% to $5M, while net loss widened to $8.2M and cash ended at $2.5M.
1. Clinical Results
BioCardia completed final data analysis from three clinical trials of its CardiAM therapy in ischemic heart failure patients, demonstrating statistically significant improvements in heart function among biomarker-elevated subgroups (p=0.02 for systolic, p=0.01 for diastolic volumes). The therapy’s overall population results did not reach statistical significance, indicating areas for further optimization.
2. Financial Performance
Total operating expenses increased by 3% to $8.3 million in 2025 as R&D spending rose 13% to $5.0 million driven by trial closeouts and regulatory activities, while SG&A expenses fell 10% to $3.3 million. Net loss widened to $8.2 million from $7.9 million, and cash and equivalents modestly increased to $2.5 million at year-end.
3. Regulatory Engagement
BioCardia is actively engaging with FDA and Japan’s PMDA, targeting filings that emphasize subgroup efficacy in patients with elevated biomarkers of heart stress. The company plans to leverage positive subgroup data to support accelerated approval pathways and inform labeling strategies.
4. HF2 Trial Progress
The CardiA HF2 confirmatory study has been launched to focus on patients showing the strongest prior response, but enrollment is proceeding slowly due to resource constraints and regulatory prioritization. Delays in patient recruitment may extend trial timelines and elevate near-term expenditures.